FREMONT, Calif., Jan. 22 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX)
announced today that its financial results for the quarter and year ended
December 31, 2000 will be issued in a press release after the close of the
U.S. financial markets on Tuesday, January 30, 2001 at 4:30 p.m. EST. Abgenix
will hold a conference call one hour after the release at 5:30 p.m. EST to
discuss these results, as well as provide financial guidance for 2001.
Interested parties may listen to the call by dialing 888-273-9889 and
mentioning the "Abgenix Conference Call." A replay of the call will be
available starting at 9 p.m. on January 30, 2001 through 11 p.m. on
February 13, 2001. To listen to the replay, dial 800-475-6701 and enter the
replay access code 564605 when prompted.
Abgenix is a biopharmaceutical company focused on the development and
commercialization of antibody therapies for a variety of diseases. The
company developed XenoMouse(TM) technology to enable the rapid generation of
high affinity, fully human antibody product candidates to essentially any
disease target appropriate for antibody therapy. Abgenix uses its XenoMouse
technology to build a large and diversified product portfolio through the
establishment of licensing arrangements with multiple pharmaceutical,
biotechnology and genomics companies and through the development of its own
internal proprietary products. For more information on Abgenix, visit the
company's website at http://www.abgenix.com.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
Company News On-Call:
http://www.prnewswire.com/comp/126548.html or fax,
800-758-5804, ext. 126548
CONTACT:
Ina Cu-Unjieng, Manager, Investor/Public
Relations of Abgenix, Inc., 510-608-4662
|
